Most patients referred for a kidney transplant in the United States never make it onto the waitlist, and nearly half never even begin the evaluation that could get them there, according to a large new analysis of electronic health records. The study followed 720,348 adults referred for transplantation and found that only about 19 percent were ultimately waitlisted — the formal step that makes a patient eligible to receive a donor organ.
The size of the drop-off is the study’s central finding. About 48 percent of referred patients never started the formal evaluation at all, meaning the steepest losses occur at the beginning of the process, before questions of organ supply or medical suitability come into play. The pipeline narrows sharply at each subsequent stage, so that a large pool of referrals resolves into a small fraction of waitlisted candidates.
Researchers drew on the Epic Cosmos database, which aggregates more than 300 million de-identified electronic health records from over 1,850 institutions, including more than a third of all US transplant centers. That scale let the authors trace individual patients across the steps that follow a referral — a vantage point that single-center studies rarely achieve, and one that captures patients who fall out of the process quietly rather than through a formal denial.
The point of the analysis is partly to challenge how success is measured. Transplant centers frequently cite referral numbers as evidence of access, but a referral is only the first step, and the data show how little it guarantees. By following what happens after the referral, the study exposes attrition that a referral count alone would hide, and it locates the biggest losses at the earliest stages, where intervention might be most feasible.
For patients, the stakes of that attrition are measured in survival. People with kidney failure depend on dialysis while they wait, and their mortality risk rises the longer they remain on it; a transplant substantially improves both life expectancy and quality of life. Time lost stalled between a referral and an evaluation is therefore not a bureaucratic delay but a clinical one, with consequences that compound the longer a patient waits.
The research was presented at the American Transplant Congress and published in the Journal of the American Society of Nephrology. Its authors frame the findings less as an indictment of any single center than as a map of where the system leaks — and an argument that programs serious about equity should track how many referred patients actually advance, not merely how many arrive at the door.